window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 17, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Novo Nordisk

  • Biomanufacturing,CDMOs & Manufacturing,Drug Development,Manufacturing,Pharmaceuticals and therapeutics,Supply Chain & Logistics

    Pharma firms localise GLP-1 supply chains as shortages and geopolitical risks grow

    Drugmakers are regionalising GLP-1 manufacturing as demand surges, shortages persist [...]

    April 17, 2026
  • Biotech,Drug Delivery & Formulation,Obesity,Pharmaceuticals and therapeutics,Research & Development,Supply Chain & Logistics,Technology and platforms

    Nanexa looks to get under the skin of GLP-1s and beyond

    Nanexa says its long-acting subcutaneous technology could reduce the dosing [...]

    November 4, 2025
  • Artificial Intelligence,Clinical Development,Pharmacovigilance,Regulatory Affairs,Research & Development

    Pistoia Alliance expands into pharmacovigilance space with launch of two new initiatives

    Collaboration efforts aim to reduce manual burden of adverse event [...]

    July 22, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Click Therapeutics secures $50M from Boehringer Ingelheim for schizophrenia digital therapy
    Categories: Clinical Development, Clinical Trials, Digital Health, Funding, Mental health, Neurosciences, Pharmaceuticals and therapeutics
  • Kainova Therapeutics doses first patient in Europe in phase 1/2 anti-CCR8 antibody trial
    Categories: Clinical Trials, Oncology
  • START appoints Salwan Al Mutar to lead clinical research in Dallas-Fort Worth
    Categories: Clinical Development, Clinical Trials, Healthcare leadership, Oncology
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top